Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...

Panelists discuss how health care providers can promote medication adherence by moving beyond labeling patients as noncompliant, instead investigating root causes such as adverse effects, financial ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Identity and Independence: Many AYAs are in a developmental stage where they are gaining autonomy. A cancer diagnosis can ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...